| Nouscom–Versant Ventures: investment, 201711 financing round Series B totalling €42m incl returning co-investor Versant Ventures |
2017-11-06 |
| Nouscom–Versant Ventures: investment, 201605 financing round Series A totalling €12m co-led by LSP + Versant Ventures |
2016-05-17 |
| Nouscom–SEVERAL: investment, 202311 financing round Series C €67.5m led by Andera Partners + Bpifrance InnoBio 2 Fund + M Ventures |
2023-11-14 |
| Nouscom–SEVERAL: investment, 201711 financing round Series B €42m led by new investor Abingworth + incl 5AM Ventures + LSP + Versant Ventures |
2017-11-06 |
| Nouscom–Revelation Partners: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Relevation Partners |
2023-11-14 |
| Nouscom–Panakès Partners: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Panakès Partners |
2023-11-14 |
| Nouscom–Minapharm: cell line, 201806– license to ProBioGen’s AGE1.CR duck cell line for production of viral vectored vaccines |
2018-06-26 |
| Nouscom–Merck (DE): investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor M Ventures |
2023-11-14 |
| Nouscom–Life Sciences Partners: investment, 201711 financing round Series B totalling €42m incl returning co-investor LSP |
2017-11-06 |
| Nouscom–Life Sciences Partners: investment, 201605 financing round Series A totalling €12m co-led by LSP + Versant Ventures |
2016-05-17 |
| Nouscom–Indaco Venture: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Indaco Venture Partners |
2023-11-14 |
| Nouscom–Huntsworth: public relations, 201711 service existent by Citigate Dewe Rogerson |
2017-11-06 |
| Nouscom–France (govt): investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor Bpifrance InnoBio 2 Fund |
2023-11-14 |
| Nouscom–EQT: investment, 202311 financing round Series C totalling €67.5m incl existing + co-investor EQT Life Sciences |
2023-11-14 |
| Nouscom–Angelini: investment, 202403 investment €7m from Angelini Ventures as Series C extension bringing total round to €75.8m |
2024-03-21 |
| Nouscom–Andera Partners: investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor Andera Partners |
2023-11-14 |
| Nouscom–Abingworth: investment, 201711 financing round Series B totalling €42m incl new + lead investor Abingworth |
2017-11-06 |
| Nouscom–5AM Ventures: investment, 202311 financing round Series C totalling €67.5m incl existing + co-investor 5AM Ventures |
2023-11-14 |
| Nouscom–5AM Ventures: investment, 201711 financing round Series B totalling €42m incl new + co-investor 5AM Ventures |
2017-11-06 |
| NofaGroup–Cotecna: investment, 201707 acquisition of NofaGroup by Cotecna Inspection SA |
2017-07-13 |
| Noema Pharma–SEVERAL: investment, 202303 financing round Series B CHF103m ($12m) co-led by Forbion + Jeito Capital |
2023-03-07 |
| Noema Pharma–SEVERAL: investment, 202012 financing round Series A CHF54m ($59m) co-led by Sofinnova Partners + Polaris Partners |
2020-12-01 |
| NN–Tecan: investment, 201903–201905 acquisition $22.5m in cash of long-term supplier of precision-machined parts w production in California + Vietnam |
2019-03-22 |
| NMD Pharma–Roche: investment, 202202 financing round totalling €35m incl existing + co-investor Roche Venture Fund |
2022-02-15 |
| NMD Pharma–Roche: investment, 201803 financing round Series A totalling €38m incl new + co-investor Roche Venture Fund |
2018-03-23 |
| Nilogen Oncosystems–Scailyte: personalised medicine, 202209 collab existent developm omics platform for analyzing tumour tissues for I-O developm |
2022-09-19 |
| Neurovance–Novartis: investment, –201703 existent investment of NVF when acquisition of Neurovance by Otsuka announced |
2017-03-03 |
| Neuron23–HBM: investment, 202203 financing round Series C totalling $100m incl existing + co-investor HBM Partners |
2022-03-30 |
| Nestlé–Seres Therapeutics: microbiome-based drug, 202107– license North America $175m upfront + $350m milestones + 50% of commercial profits |
2021-07-01 |
| Nestlé–Codexis: therapeutic enzymes, 201710– collab strategic alliance using CodeEvolver platform + incl option for ww developm of CDX-6114 |
2017-10-12 |
| Nestlé–Aimmune Therapeutics: immunotherapy, 201611– strategic collab to develop + commercialise food allergy therapies w Neslé Health Science |
2016-11-04 |
| Nemis Technologies–SEVERAL: investment, 202202 financing round Series A CHF7.75m from institutional + private investors |
2022-02-03 |
| NEC–Vaximm: cancer vaccines, 202203 acquisition of all neoantigen cancer vaccines assets by NEC OncoImmunity |
2022-03-08 |
| NEC–Vaximm: cancer vaccines, 201911– collab + option agreem for personalised neoantigen cancer vaccines |
2019-11-12 |
| Nebion–Qlucore: genomic software tools, 201801– collab integration of Qlucore Omics Explorer s/w + Genevestigator s/w for gene expression analysis |
2018-01-24 |
| Nebion–Immunai: investment, 202107 acquisition of Nebion AG by Immunai |
2021-07-29 |
| NBE Therapeutics–SEVERAL: investment, 202001 financing round Series C $22m led by existing investors BIVF + PPF Group wih all private investors |
2020-01-10 |
| NBE Therapeutics–PPF Group: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor PPF Group |
2020-01-10 |
| NBE Therapeutics–OTHER: investment, 202001 financing round Series C USD22m incl all existing private shareholders |
2020-01-10 |
| NBE Therapeutics–Optimum Strategic Communications: public relations, 202008 service existent by Optimum |
2020-08-03 |
| NBE Therapeutics–Novo Group: investment, 201806 financing round Series B CHF20m extension by Novo Holdings bringing total Series B to CHF40m |
2018-06-28 |
| NBE Therapeutics–Boehringer: investment, 202012– acquisition up to €1.18b by Boehringer |
2020-12-10 |
| NBE Therapeutics–Boehringer: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor BIVF |
2020-01-10 |
| Nagi Bioscience–Zürcher Kantonalbank: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-lead investor Swisscanto |
2023-09-28 |
| Nagi Bioscience–Zürcher Kantonalbank: investment, 202309 financing round Series A totalling CHF12.4m incl existing + co-investor ZKB |
2023-09-28 |
| Nagi Bioscience–Zürcher Kantonalbank: investment, 201912 seed financing round totalling CHF1.8m incl investor ZKB |
2019-12-20 |
| Nagi Bioscience–Verve Capital Partners: investment, 202309 financing round Series A totalling CHF12.4m incl existing + co-investor Verve Ventures |
2023-09-28 |
| Nagi Bioscience–Verve Capital Partners: investment, 201912 seed financing round totalling CHF1.8m incl investor investiere |
2019-12-20 |
| Nagi Bioscience–Switzerland (govt): grant, 202203 SERI-funded €2.5m EIC Accelerator program grant |
2022-03-21 |
| Nagi Bioscience–SEVERAL: investment, 202309 financing round Series A CHF12.4m co-led by Swisscanto + imec.xpand |
2023-09-28 |
| Nagi Bioscience–SEVERAL: investment, 201912 seed financing round CHF1.8m with investiere + ZKB + NEST Pension Fund + private investors from CH + US |
2019-12-20 |
| Nagi Bioscience–OTHER: investment, 201912 seed financing round totalling CHF1.8m incl private investors from CH + US |
2019-12-20 |
| Nagi Bioscience–NEST Pension Fund: investment, 201912 seed financing round totalling CHF1.8m incl investor NEST Pension Fund |
2019-12-20 |
| Nagi Bioscience–imec: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-lead investor imec.xpand |
2023-09-28 |
| Nagi Bioscience–Excellis: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-investor Excellis Holding |
2023-09-28 |
| mySugr–Roche: investment, 201706 acquisition of remaining shares by Roche |
2017-06-30 |
| Mysthera Therapeutics–Inflection Biosciences: PAM kinase inhibitors, 2023– license to Mysthera from Inflection |
2023-01-01 |
| Mysthera Therapeutics–Forty51 Ventures: investment, 202308 seed financing $3.5m from Forty51 Ventures announced |
2023-01-01 |
| MTIP MedTech Innovation Partners–SEVERAL: investment, 201704 final closing w addit CHF30m bringing total fund size of 1st MTIP Fund to CHF60m |
2017-04-04 |
| MTIP MedTech Innovation Partners–SEVERAL: investment, 201511–201604 1st closing CHF30m of 1st MTIP Fund |
2015-11-01 |
| Mosanna Therapeutics–SEVERAL: investment, 202207 seed financing round led by Forty51 Ventures |
2022-07-13 |
| Mosanna Therapeutics–Forty51 Ventures: investment, 202207 seed financing round incl lead investor + co-founder Forty51 Ventures |
2022-07-13 |
| Mosa Meat–Bell Food: investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor Bell Food Group |
2020-09-25 |
| Mosa Meat–Bell Food: investment, 201807 financing round Series A totalling €7.5m incl co-lead investor Bell Food Group |
2018-07-17 |
| MorphoSys–Novartis: investment, 202402– acquisition of MorphoSys voluntary public takeover offer €2.7b in cash at €68/share |
2024-02-05 |
| MoonLake–SEVERAL: investment, 202306 public offering $400m+$60m with 8m+1.2m Class A ordinary shares at $50/share |
2023-06-26 |
| MoonLake–SEVERAL: investment, 202105c financing round Series A led by BVF Partners + incl Merck KGaA |
2021-05-03 |
| MoonLake–Mo PR Advisory: public relations, 202105 service existent by Mo PR Advisory |
2021-05-03 |
| MoonLake–Merck (DE): sonelokimab, 202105– license from Merck KGaA |
2021-05-03 |
| MoonLake–Merck (DE): investment, 202105c financing round Series A incl co-investor Merck KGaA |
2021-05-03 |
| MoonLake–Consilium: public relations, 202306 service existent by Consilium Strategic Communications |
2023-06-28 |
| MoonLake–BVF Partners: investment, 202105c financing round Series A incl lead investor BVF Partners |
2021-05-03 |
| Monte Rosa Therapeutics–Versant Ventures: investment, 202005 discloses financing round Series A totalling $32.5m incl founding investor Versant |
2020-05-26 |
| Monte Rosa Therapeutics–SEVERAL: investment, 202005 emerges from stealth + discloses financing round Series A $32.5m from Versant + NEA |
2020-05-26 |
| Monte Rosa Therapeutics–New Enterprise Associates: investment, 202005 discloses financing round Series A totalling $32.5m incl investor NEA |
2020-05-26 |
| Monte Rosa Therapeutics–HBM: investment, 202103 financing round Series C totalling $95m incl existing + co-investor HBM Healthcare Investments |
2021-03-12 |
| MOMA Therapeutics–Nextech: investment, 202004 financing round Series A totalling $86m incl co-investor Nextech Invest |
2020-04-15 |
| Molecular Partners–Suvretta Capital: investment, 202007 private placement totalling CHF80.2m incl investor Suvretta Capital Management |
2020-07-06 |
| Molecular Partners–SEVERAL: investment, 202104–202106 US IPO $63.75m+$9.56m with 3m+450k ADSs at $21.25/ADS at Nasdaq |
2021-04-23 |
| Molecular Partners–SEVERAL: investment, 202007 private placement CHF80.2m from new + existing European + US institutional investors |
2020-07-06 |
| Molecular Partners–Novartis: investment, 202010 acquisition CHF40m ordinary shares at CHF23/share by Novartis resulting in 6% shareholding |
2020-10-28 |
| Molecular Partners–Monashee Investment Management: investment, 202007 private placement totalling CHF80.2m incl investor Monashee |
2020-07-06 |
| Molecular Partners–Federated Hermes Kaufmann Funds: investment, 202007 private placement totalling CHF80.2m incl investor FHKF |
2020-07-06 |
| Molecular Partners–Camber Capital Management: investment, 202007 private placement totalling CHF80.2m incl investor Camber Capital |
2020-07-06 |
| Molecular Partners–BVF Partners: investment, 202007 private placement totalling CHF80.2m with 5.53m new shares at CHF14.5/share |
2020-07-06 |
| Moderna–Lonza: biologics contract manufacturing, 202005–203004 collab strategic 10y manufacture of mRNA1273 vaccine + other Moderna products |
2020-05-01 |
| Moderna–Cabinet Privé de Conseils: public relations, 202009 service existent CPC is Swiss media contact |
2020-09-16 |
| Mithra Pharmaceuticals–BioConfidant: public relations, 202305 service existent by Cohesion Bureau |
2023-05-29 |
| Mission Therapeutics–Roche: investment, 201311 financing round Series B totalling £20m incl existing investor Roche Venture Fund |
2013-11-18 |
| MIRO Analytical–Bruker: investment, 202310 majority investment €na by Bruker |
2023-10-04 |
| Mind NRG–Minerva Neurosciences: investment, before 202008 acquisition of Mind NRG (CH) by Minerva Neurosciences |
|
| Midwest Biosolutions–Bionter: analytical instruments, 202305– collab Midwest Bio to promote + sell Bionter products + services in the US |
2023-05-08 |
| Middle Peak Medical–Symetis: investment, before 2017 acquisition by Symetis SA |
2017-01-01 |
| Microcaps–SEVERAL: investment, 202101 seed financing round CHF5m co-led by Helvetica Capital + ZKB |
2021-01-26 |
| Micro-Sphere–Ramarketing: public relations, 201708– service by Ramarketing |
2017-08-22 |
| Micro-Macinazione–Lonza: investment, 201707 acquisition €na of Micro-Macinazione from Cross Equity Fund |
2017-07-26 |
| MetrioPharm–SEVERAL: investment, 202310c financing round Series D 1st closing CHF18m |
2023-10-01 |
| Mestex–SEVERAL: investment, 2017 2nd financing round |
2017-01-01 |
| Mestex–SEVERAL: investment, 2014 1st financing round |
2014-01-01 |
| Mestex–Grünenthal: investment, 202104 acquisition 100% of Mestex AG by Grünenthal |
2021-04-12 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 9 10 11 12 
Deal: Collaboration or Financing
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
